Plenary:
Real-world observational study >1500 pts with IA, 1 year retention infliximab biosimilar CT-P13 to GP1111 switch was high. Retention was higher in originator-experienced (92vs83%) & low disease activity
Nabi H, DANBIO Abs1112 t.co/z84AMUS3GK #ACR22 @RheumNow
Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry - ACR Meeting Abstracts
Real-world observational study >1500 pts with IA, 1 year retention infliximab biosimilar CT-P13 to GP1111 switch was high. Retention was higher in originator-experienced (92vs83%) & low disease activity
Nabi H, DANBIO Abs1112 t.co/z84AMUS3GK #ACR22 @RheumNow
